QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 hc-wainwright--co-reiterates-buy-on-clene-maintains-7-price-target

HC Wainwright & Co. analyst Joseph Pantginis reiterates Clene (NASDAQ:CLNN) with a Buy and maintains $7 price target.

 clene-presents-preliminary-data-for-cnm-au8-as-a-potential-treatment-for-rett-syndrome--data-unveiled-in-oral-and-poster-presentations-on-june-19-at-the-international-rett-syndrome-foundation-2024-annual-meeting-in-westminster-colorado

CNM-Au8 is an orally administered, catalytic nanotherapeutic that targets energy metabolism via mitochondria in nervous system ...

 hc-wainwright--co-reiterates-buy-on-clene-maintains-7-price-target

HC Wainwright & Co. analyst Joseph Pantginis reiterates Clene (NASDAQ:CLNN) with a Buy and maintains $7 price target.

 clene-presented-new-long-term-cnm-au8-treatment-results-for-survival-and-neurofilament-light-levels-from-healey-als-platform-trial-open-label-extension-at-the-european-network-for-the-cure-of-als-meeting

Survival analyses with CNM-Au8 30 mg treatment compared to matched PRO-ACT controls demonstrated improved survival up to 3.5 ...

 hc-wainwright--co-reiterates-buy-on-clene-maintains-7-price-target

HC Wainwright & Co. analyst Joseph Pantginis reiterates Clene (NASDAQ:CLNN) with a Buy and maintains $7 price target.

 benchmark-reiterates-buy-on-clene-maintains-5-price-target

Benchmark analyst Bruce Jackson reiterates Clene (NASDAQ:CLNN) with a Buy and maintains $5 price target.

 hc-wainwright--co-reiterates-buy-on-clene-maintains-7-price-target

HC Wainwright & Co. analyst Joseph Pantginis reiterates Clene (NASDAQ:CLNN) with a Buy and maintains $7 price target.

 clene-q1-eps-009-misses-008-estimate-sales-7300k-miss-12000k-estimate

Clene (NASDAQ:CLNN) reported quarterly losses of $(0.09) per share which missed the analyst consensus estimate of $(0.08) by 12...

 hc-wainwright--co-reiterates-buy-on-clene-maintains-7-price-target

HC Wainwright & Co. analyst Joseph Pantginis reiterates Clene (NASDAQ:CLNN) with a Buy and maintains $7 price target.

 why-invo-bioscience-shares-are-trading-higher-by-around-73-here-are-20-stocks-moving-premarket

Shares of INVO Bioscience, Inc. (NASDAQ: INVO) rose sharply in today’s pre-market trading after reporting fourth-quarter results.